The Immune System – Products

This protocol outlines the differentiation of ATCC Assay Ready THP-1 monocytes (ATCC® TIB-202-AR™) into macrophage-like cells using PMA, eliminating the need for prior cell culturing.

This protocol outlines the differentiation of ATCC Assay Ready THP-1 monocytes (ATCC® TIB-202-AR™) into macrophage-like cells using PMA, eliminating the need for prior cell culturing.

This article explores how mRNA and VLP vaccines represent a significant advancement in vaccine technology and will play a role in protection against infectious diseases.

Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline targeting autoimmune diseases.

Refeyn, announces that it has established a new Scientific Advisory Board, chaired by Justin Benesch, Professor of Biophysical Chemistry, Oxford University and co-founder of Refeyn.

This app note highlights a multiplex immunofluorescence imaging solution for targeted spatial proteomics that provides several advantages over other spatial proteomic and transcriptomic technologies for biomarker studies.

New protein sequencing ‘proof-of-concept' method published in Nature shows promise in sequencing long, intact protein strands at single molecule resolution.

Rentschler Biopharma SE, announced the launch of an expanded service offering at its dedicated advanced therapies site in Stevenage, UK.

Scientists are constantly innovating newer technologies that allow them to understand nuances within these drugs and find ways to manufacture them more reliably.

This application note highlights the features of active-release beads compared to the established passive-release beads for the isolation, activation, cell expansion and desired early memory cell phenotype.